Back to mobile site

Goldman Sachs Reiterates Neutral Rating on Amicus Therapeutics (FOLD)

January 14, 2025 4:58 AM EST Send to a Friend
Goldman Sachs analyst Salveen Richter reiterated a Neutral rating and $14.00 price target on Amicus Therapeutics (NASDAQ: FOLD)The analyst comments ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login